A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240/PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)
A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240/PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20007, United States
Baltimore, Maryland 21224, United States
New Brunswick, New Jersey 08901, United States
Charleston, South Carolina 29425, United States
CABA, Buenos Aires C1426ABP, Argentina
Río Cuarto, Córdoba Province 5800, Argentina
Rosario, Santa Fe Province S2000CEJ, Argentina
Santiago, Region M. de Santiago 8420383, Chile
Hohenfelde B Bad Doberan, Mecklenburg-Vorpommern 18209, Germany
Budapest, 1097, Hungary
Petach Tikvah, 49100, Israel
Mexico City, Mexico City 31000, Mexico
Poznan, Greater Poland Voivodeship 61-293, Poland
Warszawa, Greater Poland Voivodeship 02-637, Poland
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-168, Poland
Bialystok, Podlaskie Voivodeship 15-276, Poland
Ternopil, Ternopil Oblast 46002, Ukraine
Vinnytsia, Vinnytsia Oblast 21018, Ukraine
Kyiv, 02091, Ukraine